Literature DB >> 21300618

Incident cervical HPV infections in young women: transition probabilities for CIN and infection clearance.

Ralph P Insinga1, Gonzalo Perez, Cosette M Wheeler, Laura A Koutsky, Suzanne M Garland, Sepp Leodolter, Elmar A Joura, Daron G Ferris, Marc Steben, Mauricio Hernandez-Avila, Darron R Brown, Elamin Elbasha, Nubia Muñoz, Jorma Paavonen, Richard M Haupt.   

Abstract

BACKGROUND: We describe transition probabilities for incident human papillomavirus (HPV) 16/18/31/33/35/45/52/58/59 infections and cervical intraepithelial neoplasia (CIN) 1 lesions.
METHODS: Women ages 16 to 23 years underwent cytology and cervical swab PCR testing for HPV at approximately 6-month intervals for up to 4 years in the placebo arm of an HPV vaccine trial. The cumulative proportion of incident HPV infections with diagnosed CIN, clearing (infection undetectable), or persisting without CIN, were estimated.
RESULTS: Most incident infections cleared, without detection of CIN, ranging at 36 months from 66.9% for HPV31 to 91.1% for HPV59. There was little variation in the 36-month proportion of incident HPV16, 18, and 31 infections followed by a CIN1 lesion positive for the relevant HPV type (range 16.7%-18.6%), with lower risks for HPV59 (6.4%) and HPV33 (2.9%). Thirty-six-month transition probabilities for CIN2 ranged across types from 2.2% to 9.1%; however, the number of events was generally too small for statistically significant differences to be seen across types for this endpoint, or CIN3.
CONCLUSIONS: Some incident HPV types appear more likely to result in diagnosed CIN1 than others. The relative predominance of HPV16, vis-à-vis some other high-risk HPV types (e.g., HPV33) in prevalent CIN2/3, appears more directly associated with relatively greater frequency of incident HPV16 infections within the population, than a higher risk of infection progression to CIN2/3. IMPACT: Nearly all incident HPV infections either manifest as detectable CIN or become undetectable within 36 months. Some HPV types (e.g., 16 and 33) appear to have similar risk of CIN2/3 despite widely varied incidence. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21300618     DOI: 10.1158/1055-9965.EPI-10-0791

Source DB:  PubMed          Journal:  Cancer Epidemiol Biomarkers Prev        ISSN: 1055-9965            Impact factor:   4.254


  43 in total

1.  Human papillomavirus genotype-specific prevalence across the continuum of cervical neoplasia and cancer.

Authors:  Nancy E Joste; Brigitte M Ronnett; William C Hunt; Amanda Pearse; Erika Langsfeld; Thomas Leete; MaryAnn Jaramillo; Mark H Stoler; Philip E Castle; Cosette M Wheeler
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-11-02       Impact factor: 4.254

2.  Trends in the Prevalence of Anogenital Warts Among Patients at Sexually Transmitted Disease Clinics-Sexually Transmitted Disease Surveillance Network, United States, 2010-2016.

Authors:  Laura M Mann; Eloisa Llata; Elaine W Flagg; Jaeyoung Hong; Lenore Asbel; Juli Carlos-Henderson; Roxanne P Kerani; Robert Kohn; Preeti Pathela; Christina Schumacher; Elizabeth A Torrone
Journal:  J Infect Dis       Date:  2019-04-16       Impact factor: 5.226

3.  A population-based study of human papillomavirus genotype prevalence in the United States: baseline measures prior to mass human papillomavirus vaccination.

Authors:  Cosette M Wheeler; William C Hunt; Jack Cuzick; Erika Langsfeld; Amanda Pearse; George D Montoya; Michael Robertson; Catherine A Shearman; Philip E Castle
Journal:  Int J Cancer       Date:  2012-06-20       Impact factor: 7.396

4.  Seroprevalence of 8 oncogenic human papillomavirus genotypes and acquired immunity against reinfection.

Authors:  Lauren Wilson; Michael Pawlita; Phillip E Castle; Tim Waterboer; Vikrant Sahasrabuddhe; Patti E Gravitt; Mark Schiffman; Nicolas Wentzensen
Journal:  J Infect Dis       Date:  2014-02-25       Impact factor: 5.226

5.  Ecological Association of Human Papillomavirus Vaccination with Cervical Dysplasia Prevalence in the United States, 2007-2014.

Authors:  Elaine W Flagg; Elizabeth A Torrone; Hillard Weinstock
Journal:  Am J Public Health       Date:  2016-10-13       Impact factor: 9.308

6.  Expression of p16INK4A in cervical precancerous lesions that is unlikely to be preventable by human papillomavirus vaccines.

Authors:  Suguna Badiga; Michelle M Chambers; Warner Huh; Isam-Eldin A Eltoum; Chandrika J Piyathilake
Journal:  Cancer       Date:  2016-08-01       Impact factor: 6.860

7.  Clinical Utility of Molecular Biomarkers in Cervical Squamous Intraepithelial Lesions in a Young Adult Population.

Authors:  Lisa Beth Spiryda; Kara M Whitaker; Amy Messersmith; Carolyn E Banister; Kim E Creek; Lucia A Pirisi-Creek
Journal:  J Low Genit Tract Dis       Date:  2016-01       Impact factor: 1.925

8.  Increased expression of programmed death (PD)-1 and its ligand PD-L1 correlates with impaired cell-mediated immunity in high-risk human papillomavirus-related cervical intraepithelial neoplasia.

Authors:  Wen Yang; Yan Song; Yun-Long Lu; Jun-Zhong Sun; Hong-Wei Wang
Journal:  Immunology       Date:  2013-08       Impact factor: 7.397

9.  Natural history of anal human papillomavirus infection in heterosexual women and risks associated with persistence.

Authors:  Anna-Barbara Moscicki; Yifei Ma; Sepideh Farhat; Julie Jay; Evelyn Hanson; Susanna Benningfield; Janet Jonte; Cheryl Godwin-Medina; Robert Wilson; Stephen Shiboski
Journal:  Clin Infect Dis       Date:  2013-12-23       Impact factor: 9.079

10.  An updated natural history model of cervical cancer: derivation of model parameters.

Authors:  Nicole G Campos; Emily A Burger; Stephen Sy; Monisha Sharma; Mark Schiffman; Ana Cecilia Rodriguez; Allan Hildesheim; Rolando Herrero; Jane J Kim
Journal:  Am J Epidemiol       Date:  2014-07-31       Impact factor: 4.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.